Intellectual Property

Recce Pharmaceuticals currently has four wholly owned patent families, which include over 40 patents or patent applications and are constantly expanding, broadening, and developing the intellectual property portfolio.

Recce is committed to protecting its intellectual property estate of patent rights and trade secrets as well as the potential commercial and/or clinical advantages this protection provides for its proprietary technology.
Recce’s patent portfolio includes issued patents and patent applications in the world’s major markets, including the United States, Europe, Japan, China and Australia.

Patent Families

Protecting Recce’s unique and highly economical manufacturing process.
FiledExpiryStatus

Australia

2028Granted

USA

2029Granted

Europe

2028Granted

Germany

2028Granted

Spain

2028Granted

France

2029Granted

UK

2028Granted

Italy

2028Granted

Sweden

2028Granted

Japan

2028Granted

China

2028Granted
Protecting Recce’s drug delivery opportunities.
FiledExpiryStatus

Australia

2035Granted

USA

2035Granted

Europe

2035Granted

Germany

2035Granted

Spain

2035Granted

France

2035Granted

UK

2035Granted

Italy

2035Granted

Sweden

2035Granted

Japan

2035Granted

China

2035Pending
Anti-virus agent and method for treatment of viral infection.
FiledExpiryStatus

Australia

2037Granted

USA

2037Granted

Europe

2037Granted

Germany

2037Granted

Spain

2037Granted

France

2037Granted

UK

2037Granted

Italy

2037Granted

Sweden

2037Granted

Japan

2037Granted

China

2037Granted

Hong Kong

2037Granted
Protecting RECCE® for use on antibiotic and pharmaceutical products and services
FiledExpiryStatus

Australia

2026Registered

USA

2026Registered

Europe

2026Registered

Japan

2026Registered

China

2026Registered

Hong Kong

2032Registered

Vietnam

2033Registered